Literature DB >> 9667971

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.

P S Dragovich1, S E Webber, R E Babine, S A Fuhrman, A K Patick, D A Matthews, S H Reich, J T Marakovits, T J Prins, R Zhou, J Tikhe, E S Littlefield, T M Bleckman, M B Wallace, T L Little, C E Ford, J W Meador, R A Ferre, E L Brown, S L Binford, D M DeLisle, S T Worland.   

Abstract

The structure-based design, chemical synthesis, and biological evaluation of various peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic modification of each amino acid residue present in the binding determinant as well as the N-terminal functionality is described. Such modifications are shown to provide irreversible HRV-14 3CP inhibitors with anti-3CP activities (kobs/[I]) ranging from 60 to 280 000 M-1 s-1 and antiviral EC50's which approach 0.15 microM. An optimized inhibitor which incorporates several improvements identified by the structure-activity studies is also described. This molecule displays very rapid irreversible inhibition of HRV-14 3CP (kobs/[I] = 800 000 M-1 s-1) and potent antiviral activity against HRV-14 in cell culture (EC50 = 0.056 microM). A 1.9 A crystal structure of an S-alkylthiocarbamate-containing inhibitor complexed with HRV-2 3CP is also detailed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667971     DOI: 10.1021/jm9800696

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

1.  Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Authors:  D A Matthews; P S Dragovich; S E Webber; S A Fuhrman; A K Patick; L S Zalman; T F Hendrickson; R A Love; T J Prins; J T Marakovits; R Zhou; J Tikhe; C E Ford; J W Meador; R A Ferre; E L Brown; S L Binford; M A Brothers; D M DeLisle; S T Worland
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Crystallization and preliminary X-ray diffraction analysis of the protease from Southampton norovirus complexed with a Michael acceptor inhibitor.

Authors:  R J Hussey; L Coates; R S Gill; J N Wright; M Sarwar; S Coker; P T Erskine; J B Cooper; S Wood; I N Clarke; P R Lambden; R Broadbridge; P M Shoolingin-Jordan
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-10-29

3.  Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model.

Authors:  K Takashima; N Matsunaga; M Yoshimatsu; K Hazeki; T Kaisho; M Uekata; O Hazeki; S Akira; Y Iizawa; M Ii
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

Review 4.  Protease inhibitors as antiviral agents.

Authors:  A K Patick; K E Potts
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

5.  Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor.

Authors:  L S Zalman; M A Brothers; P S Dragovich; R Zhou; T J Prins; S T Worland; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.

Authors:  A K Patick; S L Binford; M A Brothers; R L Jackson; C E Ford; M D Diem; F Maldonado; P S Dragovich; R Zhou; T J Prins; S A Fuhrman; J W Meador; L S Zalman; D A Matthews; S T Worland
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

7.  Structural and mutagenic analysis of foot-and-mouth disease virus 3C protease reveals the role of the beta-ribbon in proteolysis.

Authors:  Trevor R Sweeney; Núria Roqué-Rosell; James R Birtley; Robin J Leatherbarrow; Stephen Curry
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

8.  Structure of the HRV-C 3C-Rupintrivir Complex Provides New Insights for Inhibitor Design.

Authors:  Shuai Yuan; Kaiyue Fan; Zhonghao Chen; Yao Sun; Hai Hou; Ling Zhu
Journal:  Virol Sin       Date:  2020-02-26       Impact factor: 4.327

Review 9.  Current research on respiratory viral infections: Fourth International Symposium.

Authors:  Michael G Ison; John Mills; Peter Openshaw; Maria Zambon; Albert Osterhaus; Frederick Hayden
Journal:  Antiviral Res       Date:  2002-08       Impact factor: 5.970

10.  In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.

Authors:  S L Binford; P T Weady; F Maldonado; M A Brothers; D A Matthews; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.